SERUM CYTOKERATIN-19 MEASURED BY CYFRA21-1 ASSAY IN PATIENTS WITH GASTROINTESTINAL AND GYNECOLOGIC MALIGNANCY
- Authors:
- Published online on: November 1, 1994 https://doi.org/10.3892/ijo.5.5.1137
- Pages: 1137-1140
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
The serum fragment of cytokeratin 19 was measured in 130 patients with gastrointestinal, breast and gynecologic cancer and 62 patients with benign disease using CYFRA21-1 immunoradiometric assay. Patients with advanced cancer showed the highest level of serum CYFRA21-1. When the cut-off level was set at 2 ng/ml, 7 of 61 patients with earlier stage cancer were positive whereas 45 of 69 patients with advanced cancer had serum CYFRA21-1 levels over 2 ng/ml. In benign gastrointestinal and gynecologic diseases, 4 of 66 patients were positive. Retrospective evaluation revealed a good correlation between the serum CYFRA21-1 concentration and clinical course. CYFRA21-1 may be a useful tumor marker for monitoring of gastrointestinal and gynecologic malignancies.
